| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5545644 | UPJOHN | Indole derivatives |
Dec, 2016
(7 years ago) | |
| US6110940 | UPJOHN | Salts of an anti-migraine indole derivative |
Aug, 2017
(6 years ago) | |
Relpax is owned by Upjohn.
Relpax contains Eletriptan Hydrobromide.
Relpax has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Relpax are:
- US5545644
- US6110940
Relpax was authorised for market use on 26 December, 2002.
Relpax is available in tablet;oral dosage forms.
Relpax can be used as treatment of migraine with or without aura.
The generics of Relpax are possible to be released after 29 August, 2017.
Drugs and Companies using ELETRIPTAN HYDROBROMIDE ingredient
Market Authorisation Date: 26 December, 2002
Treatment: Treatment of migraine with or without aura
Dosage: TABLET;ORAL
How can I launch a generic of RELPAX before it's drug patent expiration?
More Information on Dosage
RELPAX family patents
